Trial Profile
Augmenting Response to Entecavir Using a Temporary Peginterferon Alpha-2a Add-on Strategy for the Treatment of HBeAg-Positive Chronic Hepatitis B.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Entecavir (Primary) ; Peginterferon alfa-2a (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- Acronyms ARES
- 01 Feb 2019 Results of post hoc analysis of two international RCTs (NCT00877760 and NCT01532843) published in the Alimentary Pharmacology and Therapeutics
- 01 Jul 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 13 Nov 2012 Interim results for 160 patients at 48 weeks presented at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases.